Back Nevirapien Afrikaans نيفاربين Arabic نویارپین AZB Nefirapin Welsh Nevirapin German Nevirapina Spanish نویراپین Persian Nevirapiini Finnish Névirapine French Նևիրապին Armenian

Nevirapine

Nevirapine
Clinical data
Trade namesViramune
AHFS/Drugs.comMonograph
MedlinePlusa600035
License data
Pregnancy
category
  • AU: B3
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability93% ± 9%
MetabolismLiver
Elimination half-life45 hours
ExcretionKidney: <6% (Parent drug)
Bile duct <5% (Parent drug)
Identifiers
  • 11-cyclopropyl-4-methyl-5,11-dihydro-6H- dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard100.117.250 Edit this at Wikidata
Chemical and physical data
FormulaC15H14N4O
Molar mass266.304 g·mol−1
3D model (JSmol)
  • O=C2Nc1c(ccnc1N(c3ncccc23)C4CC4)C
  • InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20) checkY
  • Key:NQDJXKOVJZTUJA-UHFFFAOYSA-N checkY
  (verify)

Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1.[5] It is generally recommended for use with other antiretroviral medications.[5] It may be used to prevent mother to child spread during birth but is not recommended following other exposures.[5] It is taken by mouth.[5]

Common side effects include rash, headache, nausea, feeling tired, and liver problems.[5] The liver problems and skin rash may be severe and should be checked for during the first few months of treatment.[5][6] It appears to be safe for use during pregnancy.[5] It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and works by blocking the function of reverse transcriptase.[5]

Nevirapine was approved for medical use in the United States in 1996.[5] It is on the World Health Organization's List of Essential Medicines.[7] It is available as a generic medication.[5]

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
  3. ^ Cite error: The named reference Viramune FDA label was invoked but never defined (see the help page).
  4. ^ Cite error: The named reference Viramune XR FDA label was invoked but never defined (see the help page).
  5. ^ a b c d e f g h i j "Nevirapine". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 3 December 2016.
  6. ^ Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 63. ISBN 9781284057560.
  7. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
From Wikipedia, the free encyclopedia · View on Wikipedia

Developed by Tubidy